Insider Transaction Report for Mark Hopman

Mark Hopman, Chief Commercial Officer of Beta Bionics, Inc., reported a sale of 275 shares of common stock on June 4, 2026. The shares were sold at a price of $12.31 per share, totaling $3,385.25. This transaction was conducted under a Rule 10b5-1 Plan adopted on May 13, 2025. Following the sale, Mr. Hopman beneficially owns 130,612 shares of Beta Bionics, Inc. common stock. The filing was made on Form 4, signed by Stephen Feider as attorney-in-fact.